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ime to End the Mixed—
nd Often Incorrect—
essages About Prevention
nd Treatment of
therosclerotic
ardiovascular Disease*
hilip Greenland, MD,
onald Lloyd-Jones, MD, SCM
hicago, Illinois
Medical research has revealed enough about the causes and
prevention of heart attacks that they could be nearly eliminated.
Yet nearly 16 million Americans are living with coronary heart
disease, and nearly half a million die from it each year. It’s not
that prevention doesn’t work, and it’s not that once someone has
a heart attack there is little to be done. In fact, said Dr.
Elizabeth Nabel, director of the National Heart, Lung and
Blood Institute at the National Institutes of Health, age-
adjusted death rates for heart disease dropped precipitously in the
past few decades, and prevention and better treatment are major
reasons why. But the concern, Dr. Nabel and others say, is that
much more could be done. In many ways, scientists’ hard-won
and increasingly detailed understanding of what causes heart
disease and what to do for it often goes unknown or ignored (1).
hile we were preparing this editorial, the above quote
ppeared on the front page of the April 8, 2007 issue of the
ew York Times (1). How stark the contrast between this
ather glum view of the progress of cardiovascular research
ver the past 50 years versus the triumphant editorial in
cience in 1996 proclaiming the “end of heart attacks by the
entury” (2). The latter, by Brown and Goldstein (2), Nobel
See page 2128
rize winners for their brilliant work on the mechanics and
ole of the low-density lipoprotein (LDL) receptor in
holesterol regulation and control, predicted that current
nowledge, if fully applied, could end heart attacks
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Departments of Preventive Medicine and Medicine, Northwestern
niversity Feinberg School of Medicine, Chicago, Illinois.ithin a short time. Which view is the correct one: the
ailure of our research to reach full translation, or the great
otential based on the accomplishments of cardiovascular
esearch that turned the heart attack epidemic around? Of
ourse, both are true—the potential is there, but the reality
s not, for, as Dr. Nabel said, our great knowledge of the
auses and treatment of heart disease often goes unknown or
gnored.
The paper by Ford and Capewell (3) in this issue of the
ournal demonstrates that the battle is not over, and, in fact,
f we are not careful, the enemy will rise again. Although we
ave prided ourselves on the continuing decline in age-
djusted mortality rates from coronary heart disease (CHD),
e have missed until now the fact that younger people, as
emonstrated by Ford and Capewell (3), have reached a
adir and the death rate seems to be on the increase again.
hese are the best data that we have in this country given
hat we lack a true national surveillance system (4). They
re, indeed, the same data upon which we have based our
onclusions about the fall in age-adjusted mortality over the
ast 2 to 3 decades. The ominous finding of a possible
ncrease in the age-specific CHD death rate in young adults
hould not be ignored. It is time to stop giving the mixed
essage that “we are winning the war on heart disease, but
ay attention to your risk factors anyway.”
The new data by Ford and Capewell (3) suggest that the
essage should immediately be revised: we are now starting
o lose the battle against heart disease, and if we continue to
gnore what we already know about prevention and treat-
ent of risk factors, we will suffer the consequences with
ncreased morbidity, increased mortality, and reduced lon-
evity among America’s men and women now in their 30s,
0s, and 50s. As Olshansky et al. (5) predicted in 2005, the
teady rise in life expectancy during the past 2 centuries may
oon come to an end. It is time to give a straight message to
ur young people, and to ourselves as cardiologists and
ardiovascular researchers, that our first priority must be to
pply the knowledge that we already have. In the paragraphs
hat follow, we will summarize what we think the prevention
essage must be if we are to capitalize on the achievements
f our research and also benefit from the warning of
mportant papers like the one published in this issue of the
ournal (3).
. Heart attacks rarely occur in the absence of the major
isk factors (adverse levels of blood cholesterol, blood
ressure, smoking, diabetes). In the past, it was com-
only held that only one-half of myocardial infarctions
ccurred in people with elevations of the traditional risk
actors. This incorrect belief started appearing in the car-
iovascular literature around 1974 (6) and occasionally still
ppears in contemporary journal articles. However, as dem-
nstrated by 2 back-to-back articles in 2003 (7,8), myocar-
ial infarction or coronary death is uncommon in the
bsence of concurrent or antecedent risk factor exposure to
dverse levels of 1 or more of the major risk factors. In fact,
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Editorial Comment November 27, 2007:2133–5n the Framingham Heart study, where multiple antecedent
isk factor measures were available in all study participants,
0% to 100% of all CHD events occurred in people with at
east 1 CHD risk factor present before the event (7).
. Absence of the major cardiovascular risk factors is
ighly protective against cardiovascular morbidity and
ortality. Several major studies have demonstrated the
emarkable protection from cardiovascular morbidity and
ortality afforded to people who have reached middle age
ithout any of the major CHD risk factors being present.
or example, Stamler et al. (9) reported in 1999 that
ge-adjusted risks of CHD mortality were 77% to 92%
ower among cohorts of men and women without any major
HD risk factor versus the entire balance of the cohort with
t least 1 risk factor. In addition, the all-cause mortality
ates ranged from 40% to 58% lower for those without any
ajor risk factor compared with all others. Estimated
reater life expectancy for low-risk groups ranged from 5.8
o 9.5 years, suggesting the marked benefits of reaching
iddle age without any major risk factor prevalent. These
ndings have now also been confirmed and extended using
he technique of lifetime risk estimation in both the Fra-
ingham (10) and the Chicago Heart Association (11)
tudies. Thus, a formula starts to emerge that preventing the
ccurrence of the risk factors in early life could potentially
revent the vast majority of CHD and truly put an end to
he CHD epidemic.
. Unfortunately, very few people in America have no
ajor risk factors present. In an analysis of the Third
ational Health and Nutrition Examination (NHANES-3)
ata, Vasan et al. (12) reported that 1% of men between
he ages of 35 and 74 years of age had all optimal risk factors
defined as systolic blood pressure 120 mm Hg and
iastolic blood pressure 80 mm Hg, LDL cholesterol
100 mg/dl, high-density lipoprotein cholesterol 59 mg/
l, fasting glucose level 110 mg/dl or 2-h glucose level
140 mg/dl, and never smoking). For women, between
ges 35 and 44, 8.9% had all optimal risk factors, whereas by
ge 55 to 74 years, 1% of women still had all CHD risk
actors in the optimal ranges.
. Elevated risk factors in young adulthood appear to be
major consequence of weight gain. In a recent analysis
13) from the CARDIA (Coronary Artery Risk Develop-
ent in Young Adults) study, white and black adults 18 to
0 years of age at the initial examination in 1985 to 1986
ere stratified into groups by baseline body mass index
BMI) and by change in BMI (stable/decreased, increased
2 kg/m2, or fluctuating) across 6 examinations between
ears 0 and 15 of the study. Changes in metabolic syndrome
omponents were compared between groups. Among 1,358
en and 1,321 women, only 16.3% maintained a stable
MI, 73.9% had an increased BMI, and 9.8% had a
uctuating BMI. Over 15 years, participants with stable
MI had essentially unchanged levels of metabolic syn-
rome components, regardless of baseline BMI, whereas
hose with increased BMI had progressively worsening wevels of all metabolic syndrome components. The incidence
f metabolic syndrome at year 15 was lower in the stable
MI group (2.2%) compared with that seen in the increased
MI group (18.8%; p  0.001). The commonly held view
hat adverse progression of metabolic syndrome components
ith advancing age is inevitable was not confirmed by this
tudy. Young adults who maintained stable BMI over time
ad minimal progression of risk factors and a lower inci-
ence of metabolic syndrome, regardless of baseline BMI.
owever, weight gain, accompanied by adverse risk factor
rogression was all too common, occurring in nearly 3 of 4
eople. Clearly, weight gain has many behavioral compo-
ents that are not easily addressed by medical therapy.
urther research is desperately needed to discover effective
ethods for behavior modification at the individual and
ublic health levels, in order at least to achieve weight
aintenance in larger segments of the population. And even
ore urgently needed is research on prevention of weight
ain in larger numbers of people.
A reasonable conclusion from the data presented in the
receding text is that prevention of major CHD risk factors,
ost particularly through better efforts to prevent weight
ain in young adulthood, could lead to a further marked
eduction in CHD morbidity, mortality, and an even further
mprovement in overall life expectancy in the U.S. Con-
ersely, the continuing obesity epidemic, with its associated
dverse effects on multiple cardiovascular risk factors, is a
ighly likely explanation for the newly reversed decline in
ge-specific CHD mortality rates among younger Amer-
cans, as shown by Ford and Capewell (3). Although this
nalysis can readily be criticized for its over-simplification
f the rather complex problem that is atherosclerotic
ardiovascular disease, its simplicity is perhaps just the
essage that we now need to turn the tide once again
gainst the enemy of coronary heart disease. The message
hat must be now promulgated is not the mixed message
“we have made great progress, but pay attention to your
isk factors anyway”).
Instead, the message should be straight and clear: we
now what the major causes of CHD are, and they consist
f adverse levels of blood pressure, LDL cholesterol, diabe-
es, overweight and obesity, and cigarette smoking. These
isk factors are generally preventable through smoking
bstinence or cessation and appropriate attention to diet,
xercise, and avoidance of weight gain and obesity, the latter
merging as increasingly important if we want to continue
o win against CHD. Indeed, there is extensive evidence
hat the gains against CHD mortality that were observed in
he U.S. and many countries from 1965 to 2000 were
verwhelmingly due to improvements in population levels
f risk factors (themselves a result of dietary changes,
moking cessation, and other public health programs) rather
han due to invasive procedures or new medications (14,15).
ithout increased and concerted vigilance toward risk
actor prevention in early life and young adulthood, we will
itness increasing losses in the battle against health enemy
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